Teva Pharmaceutical Industries Limited Stock Other OTC
Stocks
TEVJF
IL0006290147
Pharmaceuticals
OTC Markets Traded| Market Cap | 36.5B 31.99B 29.69B 27.29B 51.42B 3,523B 52.17B 354B 138B 1,724B 137B 134B 5,954B | P/E 2026 * |
38.7x | P/E 2027 * | 17.1x |
|---|---|---|---|---|---|
| Enterprise Value | 47.67B 41.77B 38.77B 35.63B 67.14B 4,600B 68.13B 462B 181B 2,251B 179B 175B 7,775B | EV / Sales 2026 * |
2.87x | EV / Sales 2027 * | 2.61x |
| Free-Float |
88.61% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 2022-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 2019-12-21 |
Matthew Shields
COO | Chief Operating Officer | 52 | 2024-06-02 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 2008-12-31 |
Sol Barer
CHM | Chairman | 78 | 2017-02-05 |
Rosemary Crane
BRD | Director/Board Member | 65 | 2015-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 36.5B | |
| -1.05% | +0.55% | +49.79% | +153.20% | 1,048B | |
| +2.00% | +3.49% | +52.22% | +49.42% | 603B | |
| -1.09% | +3.76% | +35.37% | +76.91% | 452B | |
| -0.42% | +1.65% | +30.05% | +21.05% | 327B | |
| -0.16% | +2.39% | +36.91% | +37.33% | 283B | |
| +1.68% | +2.73% | +24.14% | +17.94% | 259B | |
| -1.40% | -0.06% | -22.24% | -42.39% | 219B | |
| -0.05% | +2.16% | +19.75% | +55.49% | 198B | |
| +0.05% | -1.03% | +18.31% | +67.83% | 162B | |
| Average | -0.01% | +1.74% | +27.14% | +48.53% | 394.63B | |
| Weighted average by Cap. | -0.05% | +1.69% | +36.11% | +73.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.64B 14.58B 13.53B 12.43B 23.43B 1,605B 23.78B 161B 63.1B 785B 62.45B 61.1B 2,714B | 17.23B 15.1B 14.02B 12.88B 24.27B 1,663B 24.63B 167B 65.36B 814B 64.69B 63.29B 2,811B |
| Net income | 1.31B 1.15B 1.06B 979M 1.84B 126B 1.87B 12.69B 4.97B 61.81B 4.91B 4.81B 214B | 2.46B 2.16B 2B 1.84B 3.47B 238B 3.52B 23.87B 9.34B 116B 9.25B 9.05B 402B |
| Net Debt | 11.16B 9.78B 9.08B 8.34B 15.72B 1,077B 15.95B 108B 42.34B 527B 41.9B 41B 1,821B | 8.41B 7.37B 6.84B 6.28B 11.84B 811B 12.01B 81.46B 31.88B 397B 31.56B 30.88B 1,371B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
